Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study
Authors:
- John A. BittlJBJohn A. Bittl
- Bernard R. ChaitmanBCBernard R. Chaitman
- Frederick FeitFFFrederick Feit
- William KimballWKWilliam Kimball
- Eric J. TopolETEric J. Topol
- 1 December 2001
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 142 (6) , 952-959
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Defining the Optimal Activated Clotting Time During Percutaneous Coronary InterventionCirculation, 2001
- Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trialThe Lancet, 2000
- Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trialThe Lancet, 1999
- Platelet Activation With Unfractionated Heparin at Therapeutic Concentrations and Comparisons With a Low-Molecular-Weight Heparin and With a Direct Thrombin InhibitorCirculation, 1998
- Randomized, Double-blind Comparison of Hirulog Versus Heparin in Patients Receiving Streptokinase and Aspirin for Acute Myocardial Infarction (HERO)Circulation, 1997
- Relation Between Activated Clotting Time During Angioplasty and Abrupt ClosureCirculation, 1996
- Length of Hospital Stay and Complications After Percutaneous Transluminal Coronary AngioplastyCirculation, 1995
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4.Circulation, 1994
- Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.Journal of Clinical Investigation, 1990